PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reports that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (�XGen�), a Nevis Island limited liability company.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.�s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix�s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (�PRTMI�) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
ADVENTRX Pharmaceuticals, Inc. (NYSE:ANX) reports that the Company�s Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday September 14, 2010 at 11:40 a.m. Eastern time, in the Hubbard Salon at the New York Palace Hotel in New York.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals website. An archived presentation will be available on the website for 30 days.
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.
ADVENTRX Pharmaceuticals� lead product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine, and ANX-514 (docetaxel lyophilized emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs.
BSD Medical Corporation (NASDAQ: BSDM) has received certification that the MicroThermX Microwave Ablation System (MTX-180) meets all requirements for safety and performance needed for compliance with the IEC 60601-1, safety standard, �Medical Electrical Equipment Part 1: General Requirements for Safety.� IEC 60601-1 is the global benchmark for safety of medical equipment and is a crucial tool for demonstrating compliance with regulatory requirements around the world, including the requirements for CE Marking and FDA clearance. Receipt of this certification will allow BSD to add the TUV safety mark to the MTX-180 system. Nearly all hospitals and clinics in the U.S. require a safety mark on equipment prior to purchase.
�The receipt of this safety certification for the MTX-180 is a significant milestone for the Company and critical for marketing the MTX-180 system in the U.S. and Europe, as well as in most markets throughout the world,� stated Harold Wolcott, President of BSD. �We are excited to have completed this important step toward marketability of the MTX-180.�
T�VRheinland performed independent testing of all components and operations of the MTX-180 and performed an on-site assessment of BSD�s internal control systems for ensuring product quality before it accredited the MTX-180. T�VRheinland is a nationally recognized testing laboratory and is recognized as a U.S. National Certification Body by the International Electrotechnical Commission.
No comments :
Post a Comment